Detection of JAK2 V617F mutation for myeloproliferative disorder diagnosis.
This PCR-based test detects the presence of the JAK2 V617F mutation in exon 14, commonly associated with myeloproliferative neoplasms (MPNs) such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The mutation leads to abnormal blood cell production and helps in the diagnostic workup of unexplained erythrocytosis, thrombocytosis, or leukocytosis.
Covid Safety
Assured
Free Report
Counselling
Recommended for You
How our test process works!
Overview:
This is a molecular diagnostic test used to detect the V617F mutation in the JAK2 gene (Exon 14), commonly associated with myeloproliferative neoplasms (MPNs) such as:
-
Polycythemia Vera (PV)
-
Essential Thrombocythemia (ET)
-
Primary Myelofibrosis (PMF)
Risk Assessment:
Presence of the mutation is strongly linked with:
-
Increased risk of thrombosis
-
Progression to myelofibrosis or leukemia
-
Higher blood cell counts (RBCs, WBCs, or platelets)
Normal Range:
-
Normal (Negative): No JAK2 V617F mutation detected.
Interpretation:
-
Positive: JAK2 V617F mutation detected → Suggestive of MPN; needs clinical correlation.
-
Negative: Mutation not detected → Does not rule out MPN completely; further testing (e.g., Exon 12 or CALR/MPL mutations) may be needed based on clinical suspicion.
Sample Type:
-
Peripheral blood (EDTA)
Frequently Asked Question
PCR Jak-2 Mutation (EXON-14, V617F)
Detection of JAK2 V617F mutation for myeloproliferative disorder diagnosis.
This PCR-based test detects the presence of the JAK2 V617F mutation in exon 14, commonly associated with myeloproliferative neoplasms (MPNs) such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The mutation leads to abnormal blood cell production and helps in the diagnostic workup of unexplained erythrocytosis, thrombocytosis, or leukocytosis.
Covid Safety
Assured
Free Report
Counselling